Health
Wall Street changes its tune on this healthcare stock. Why we were always bullish
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks were modestly higher Monday as the market awaits key economic data. Traders will be mulling over the consumer price index Tuesday, retail sales Thursday, and the producer […]
Read More
Defense Secretary Lloyd Austin re-hospitalized for bladder issue
US Defense Secretary Lloyd Austin takes questions during a press conference at the Pentagon in Washington, DC, on February 1, 2024. Andrew Caballero-reynolds | Afp | Getty Images Defense Secretary Lloyd Austin was taken back to the hospital on Sunday afternoon for symptoms related to a possible bladder issue, the Pentagon announced. Austin is battling […]
Read More
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said […]
Read More
Portfolio health care name turns its luck around thanks to management's AI push
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. U.S. stocks were mostly higher on Friday. The S & P 500 was on track for a fifth positive week in a row. The broad market index topped 5,000 […]
Read More
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on […]
Read More
Wall Street gives 2 of our healthcare stocks well-deserved price target bumps
Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of MRI machines and other medical equipment on Tuesday delivered […]
Read More
GEHC stock finally gets some respect after earnings. Those betting against it got slammed
Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management’s upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82. Total […]
Read More
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. The initial study […]
Read More
Wall Street says Big Tech needs to take a breather after huge run. Here's our take
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is […]
Read More
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. […]
Read More